112 related articles for article (PubMed ID: 28589549)
21. Hepatocyte-specific magnetic resonance imaging contrast agents.
Fidler J; Hough D
Hepatology; 2011 Feb; 53(2):678-82. PubMed ID: 21274888
[No Abstract] [Full Text] [Related]
22. Inflammatory hepatic adenomas: Characterization with hepatobiliary MRI contrast agents.
Glockner JF; Lee CU; Mounajjed T
Magn Reson Imaging; 2018 Apr; 47():103-110. PubMed ID: 29221964
[TBL] [Abstract][Full Text] [Related]
23. Low-dose gadobenate dimeglumine-enhanced MRI in the detection and characterization of focal liver lesions.
Kirchin MA; Spinazzi A
Acad Radiol; 2002 May; 9 Suppl 1():S121-6. PubMed ID: 12019846
[No Abstract] [Full Text] [Related]
24. Quantitative parameters obtained from gadobenate dimeglumine-enhanced MRI at the hepatobiliary phase can predict post-hepatectomy liver failure and overall survival in patients with hepatocellular carcinoma.
Cai S; Lin X; Sun Y; Lin Z; Wang X; Lin N; Zhao X
Eur J Radiol; 2022 Sep; 154():110449. PubMed ID: 35901599
[TBL] [Abstract][Full Text] [Related]
25. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation.
Vogl TJ; Stupavsky A; Pegios W; Hammerstingl R; Mack M; Diebold T; Lodemann KP; Neuhaus P; Felix R
Radiology; 1997 Dec; 205(3):721-8. PubMed ID: 9393527
[TBL] [Abstract][Full Text] [Related]
26. Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma.
Reizine E; Ronot M; Ghosn M; Calderaro J; Frulio N; Bioulac-Sage P; Trillaud H; Vilgrain V; Paradis V; Luciani A
Eur Radiol; 2021 May; 31(5):3417-3426. PubMed ID: 33146794
[TBL] [Abstract][Full Text] [Related]
27. Incorporating the hepatobiliary phase of gadobenate dimeglumine-enhanced MRI in the diagnosis of hepatocellular carcinoma: increasing the sensitivity without compromising specificity.
Cortis K; Liotta R; Miraglia R; Caruso S; Tuzzolino F; Luca A
Acta Radiol; 2016 Aug; 57(8):923-31. PubMed ID: 26567965
[TBL] [Abstract][Full Text] [Related]
28. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT.
Marin D; Di Martino M; Guerrisi A; De Filippis G; Rossi M; Ginanni Corradini S; Masciangelo R; Catalano C; Passariello R
Radiology; 2009 Apr; 251(1):85-95. PubMed ID: 19332848
[TBL] [Abstract][Full Text] [Related]
29. Predictors of dysplastic nodule diagnosis in patients with liver cirrhosis on unenhanced and gadobenate dimeglumine-enhanced MRI with dynamic and hepatobiliary phase.
Quaia E; De Paoli L; Pizzolato R; Angileri R; Pantano E; Degrassi F; Ukmar M; Cova MA
AJR Am J Roentgenol; 2013 Mar; 200(3):553-62. PubMed ID: 23436844
[TBL] [Abstract][Full Text] [Related]
30. Effect of increasing the flip angle during the hepatocyte phase of gadobenate dimeglumine-enhanced 1.5T MRI in cirrhotic patients with hepatocellular carcinoma.
Lee EJ; Kim DJ; Cho ES; Kim KA
J Magn Reson Imaging; 2016 Mar; 43(3):713-9. PubMed ID: 26290384
[TBL] [Abstract][Full Text] [Related]
31. Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis.
Fowler KJ; Brown JJ; Narra VR
Hepatology; 2011 Dec; 54(6):2227-37. PubMed ID: 21932400
[TBL] [Abstract][Full Text] [Related]
32. Efficacy comparison of multi-phase CT and hepatotropic contrast-enhanced MRI in the differential diagnosis of focal nodular hyperplasia: a prospective cohort study.
Nowicki TK; Markiet K; Izycka-Swieszewska E; Dziadziuszko K; Studniarek M; Szurowska E
BMC Gastroenterol; 2018 Jan; 18(1):10. PubMed ID: 29334905
[TBL] [Abstract][Full Text] [Related]
33. Comparison of superparamagnetic iron oxide-enhanced and gadobenate dimeglumine-enhanced dynamic MRI for detection of small hepatocellular carcinomas.
Kim YK; Kim CS; Lee YH; Kwak HS; Lee JM
AJR Am J Roentgenol; 2004 May; 182(5):1217-23. PubMed ID: 15100122
[TBL] [Abstract][Full Text] [Related]
34. Impact of hepatobiliary phase liver MRI versus Contrast-Enhanced Ultrasound after an inconclusive extracellular gadolinium-based contrast-enhanced MRI for the diagnosis of benign hepatocellular tumors.
Tselikas L; Pigneur F; Roux M; Baranes L; Costentin C; Roche V; Calderaro J; Herin E; Laurent A; Zafrani E; Azoulay D; Mallat A; Rahmouni A; Luciani A
Abdom Radiol (NY); 2017 Mar; 42(3):825-832. PubMed ID: 27704147
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI.
Choi SH; Lee JM; Yu NC; Suh KS; Jang JJ; Kim SH; Choi BI
AJR Am J Roentgenol; 2008 Aug; 191(2):529-36. PubMed ID: 18647927
[TBL] [Abstract][Full Text] [Related]
36. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine.
Grazioli L; Morana G; Federle MP; Brancatelli G; Testoni M; Kirchin MA; Menni K; Olivetti L; Nicoli N; Procacci C
Radiology; 2001 Dec; 221(3):731-9. PubMed ID: 11719669
[TBL] [Abstract][Full Text] [Related]
37. Multicenter testing of gadobenate dimeglumine in magnetic resonance imaging of focal liver disease.
Spinazzi A; Pirovano G; Ratcliffe G; Pezzoli C; Rosati G
Acad Radiol; 1996 Aug; 3 Suppl 2():S415-6. PubMed ID: 8796618
[No Abstract] [Full Text] [Related]
38. Hepatocellular Carcinoma: Retrospective Evaluation of the Correlation Between Gadobenate Dimeglumine-Enhanced Magnetic Resonance Imaging and Pathologic Grade.
Huang X; Xiao Z; Zhang Y; Lin N; Xiong M; Huang X; Chen Q; Cao D
J Comput Assist Tomogr; 2018; 42(3):365-372. PubMed ID: 29369947
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Hepatocellular Carcinoma Tumor Response After Transcatheter Arterial Chemoembolization Using Gadobenate Dimeglumine-Enhanced Liver Magnetic Resonance.
Chu LC; Pozzessere C; Corona-Villalobos CP; Castaños S; Rastegar N; Halappa V; Bonekamp S; Emurano E; Kamel IR
J Comput Assist Tomogr; 2016; 40(6):856-862. PubMed ID: 27680411
[TBL] [Abstract][Full Text] [Related]
40. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
De Gaspari A; De Cobelli F; Del Maschio A
Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]